Adult urology| Volume 58, ISSUE 6, P960-963, December 2001

Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms1


      Objectives. To assess the effects of saw palmetto on urinary symptoms, sexual function, and urinary flow rate in men with lower urinary tract symptoms using a double-blind, randomized, placebo-controlled trial.
      Methods. The eligible patients were 45 years of age or older and had an International Prostate Symptom Score of 8 or greater. After a 1-month placebo run-in period, 85 men were randomized to receive saw palmetto or placebo for 6 months. Patients were evaluated using the International Prostate Symptom Score, a sexual function questionnaire, and by measurement of the urinary flow rate.
      Results. The mean symptom score decreased from 16.7 to 12.3 in the saw palmetto group compared with 15.8 to 13.6 in the placebo group (P = 0.038). The quality-of-life score improved to a greater degree in the saw palmetto group, but this difference was not statistically significant. No change occurred in the sexual function questionnaire results in either group. The peak flow rate increased by 1.0 mL/s and 1.4 mL/s in the saw palmetto and placebo groups, respectively (P = 0.73).
      Conclusions. Saw palmetto led to a statistically significant improvement in urinary symptoms in men with lower urinary tract symptoms compared with placebo. Saw palmetto had no measurable effect on the urinary flow rates. The mechanism by which saw palmetto improves urinary symptoms remains unknown.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Marwick C.
        Growing use of medicinal botanicals forces assessment by drug regulators.
        JAMA. 1995; 273: 607-609
        • Astin J.A.
        Why patients use alternative medicine.
        JAMA. 1998; 279: 1548-1553
        • Furnham A.
        • Forey J.
        The attitudes, behaviors, and beliefs of patients of conventional vs. complementary (alternative) medicine.
        J Clin Psychol. 1994; 50: 458-469
        • Lowe F.C.
        • Fagelman E.
        Phytotherapy in the treatment of benign prostatic hyperplasia.
        Urology. 1999; 53: 671-678
        • Descotes J.L.
        • Rambeaud J.J.
        • Deschaseaux P.
        • et al.
        Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders.
        Clin Drug Invest. 1995; 9: 291-297
        • Cukier J.
        • Ducassou J.
        • Le Guillou M.
        • et al.
        Permixon versus placebo.
        C R Ther Pharmacol Clin. 1985; 4: 15-21
        • Reece Smith H.
        • Memom A.
        • Smart C.J.
        • et al.
        The value of Permixon in benign prostatic hypertrophy.
        Br J Urol. 1986; 58: 36-40
        • Tasca A.
        • Barulli M.
        • Cavazzana A.
        • et al.
        Trattemento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens.
        Minerva Urol Nefrol. 1985; 37: 87-91
        • Marks L.S.
        • Partin A.W.
        • Epstein J.I.
        • et al.
        Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
        J Urol. 2000; 163: 1451-1456
        • Wilt T.J.
        • Ishani A.
        • Stark G.
        • et al.
        Saw palmetto extracts for treatment of benign prostatic hyperplasia.
        JAMA. 1998; 280: 1604-1609
        • Boyle P.
        • Robertson C.
        • Lowe F.
        • et al.
        Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia.
        Urology. 2000; 55: 533-539
        • Roehrborn C.G.
        Urology Times. 2000; 28: 33-34
        • McConnell J.D.
        • Barry M.J.
        • Bruskewitz R.C.
        Clinical Practice Guideline. Benign Prostatic Hyperplasia. United States Department of Health and Human Services, Agency for Health Care Policy and Research, Rockville, Maryland1994
        • O’Leary M.P.
        • Fowler F.J.
        • Lenderking W.R.
        • et al.
        A brief male sexual function inventory for urology.
        Urology. 1995; 46: 697-706
        • Bales G.T.
        • Christiano A.P.
        • Kirsh E.J.
        • et al.
        Phytotherapeutic agents in the treatment of lower urinary tract symptoms.
        Urology. 1999; 54: 86-89
        • Champault G.
        • Patel J.C.
        • Bonnard A.M.
        A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.
        Br J Clin Pharmacol. 1984; 18: 461-462
        • Emili E.
        • Lo Cigno M.
        • Petrone U.
        Risultati clinic su un nuovo farmaco nelle terapia dell’ipertrofia della prostate (Permixon).
        Urologia. 1983; 50: 1042-1048
        • Gerber G.S.
        • Zagaja G.P.
        • Bales G.T.
        • et al.
        Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms.
        Urology. 1998; 51: 1003-1007
        • Angell M.
        • Kassirer J.P.
        Alternative medicine—the risks of untested and unregulated remedies.
        N Engl J Med. 1998; 339: 785-787

      Linked Article